Hawaii Immunization Registry
PRD Region
*   *   *   *   *
Org Code:
Username:
Password:
********************
DO NOT ATTEMPT TO LOG ON UNLESS YOU ARE AN AUTHORIZED USER.
**********

Validation Errors

  • The Org Code, Username and Password combination is invalid.

  Hot Topics HT-1 HT-2 HT-3 HT-4 HT-5 HT-6 HT-7 HT-8 HT-9 HT-10 HT-11 HT-12 HT-13 HT-14 HT-15
HIR Announcements Posted on 10/24/2022
COVID-19 vaccines in HIR:
Pfizer-BioNTech bivalent booster 12y (mRNA-LNP, p free, 30 mcg/0.3 mL) CVX 300
Pfizer-BioNTech bivalent booster 5-11y (mRNA LNP-S, bivalent, PF, 10mcg/0.2mL) CVX 301
Pfizer Tris - Adult/Adolescent (mRNA, PF, 30 mcg/0.3 mL, tris) CVX 217
Pfizer COVID-19 Vaccine (mRNA, LNP-S, PF, 0.3mL) CVX 208
Pfizer COVID-19 Peds 6m-4 yrs (mRNA,PF,3 mcg/0.2 mL dose, 6M-4Y) CVX 219
Pfizer COVID-19 Peds 5-11 yrs (mRNA, PF, 10 mcg/0.2 mL) CVX 218
Novavax (5mcg/0.5 mL,primary series,adult) CVX 211
Moderna COVID-19 Vaccine (mRNA, LNP-S, PF, 0.5mL) CVX 207
Moderna COVID-19 Peds 6M-5 yrs (mRNA LNP-S PF ped 25 mcg/0.25 mL) CVX 228
Moderna COVID-19 Bivalent Booster (mRNA-LNP,bivalent, p free, 50 mcg/0.5 mL) CVX 229
Moderna COVID-19 Bivalent Booster 6-11y (mRNA LNP-S, bivalent, p free, 25 mcg/0.25 mL) CVX 229
Moderna COVID19 6Y-11Y (mRNA, LNP-S, PF, 50 mcg/0.5 mL) CVX 221
Janssen COVID-19 Vaccine (vector-nr, rS-Ad26, PF, 0.5 mL) CVX 212

HIR Enrollment Period:
Reminding everyone that enrollment period for 2023 will be happening between November 15 and January 31: Facility Agreement to be submitted via the new HIR ONLINE form and Confidentiality & Security Statement via the same paper form.

HIR Unavailability:
HIR is unavailable daily between 3:00 a.m. to 7:00 a.m. HST for system processing.

Race Codes:
HIR was recently enhanced to accept additional race codes - 28 total (go to Forms tab/HIR Data Exchange Specifications Section). We are asking providers to obtain more than one race information from patients before submitting patient records to HIR. These additional race values will help improve understanding of vaccination coverage within population subgroups and identify potential disparities and pockets of need.


. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .